The "albumin effect" and drug glucuronidation: Bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities

Drug Metabolism and Disposition

Volumn 36, Issue 6, 2008, Pages 1056-1062

  Rowland, Andrew ^a   Knights, Kathleen M ^a   Mackenzie, Peter I ^a   Miners, John O ^a,b  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; BOVINE SERUM ALBUMIN; FATTY ACID; GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; HUMAN SERUM ALBUMIN; HYMECROMONE; LINOLEIC ACID; OLEIC ACID; PROPOFOL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIVER CLEARANCE; LIVER MICROSOME; MALE; MICHAELIS CONSTANT; PREDICTION; PRIORITY JOURNAL;

ADULT; AGED; ANIMALS; CATTLE; CELL LINE; FEMALE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; HYMECROMONE; MALE; MICROSOMES, LIVER; MIDDLE AGED; PROPOFOL; RECOMBINANT PROTEINS; SERUM ALBUMIN; SERUM ALBUMIN, BOVINE;

BOVINAE;

EID: 44149117018     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.021105     Document Type: Article

References (33)

1. Bailie GR, Cockshott ID, Douglas EJ, and Bowles BJM (1992) Pharmacokinetics of propofol during and after long term continuous infusion for maintenance of sedation in ICU patients. Br J Anaesth 68:486-491.
2. Boase S and Miners JO (2002) In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigation with the model substrate zidovudine. Br J Clin Pharmacol 54:493-503.
3. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, and Miners JO (2005) Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 60:423-433.
4. Court MH (2005) Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol 400:104-116.
5. Court MH, Krishnaswamy S, Hoa Q, Duan SX, Patten CJ, von Moltke LL, and Greenblatt DJ (2003) Evaluation of 3′-azido-3′-deoxymethymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 31:1125-1133.
6. Engtrakul JJ, Foti RS, Strelevitz TJ, and Fisher MB (2005) Altered AZT (3′-azido-3′-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment. Drug Metab Dispos 33:1621-1627.
7. Gepts E, Camu F, Cockshott ID, and Douglas EJ (1987) Disposition of propofol administered as constant rate intravenous infusion in humans. Anesth Analg 66:1256-1263.
8. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
9. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
10. Kiang TK, Ensom MH, and Chang TK (2005) UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106:97-132.
11. Kubota T, Lewis BC, Elliot DJ, Mackenzie PI, and Miners JO (2007) Critical roles of residues 36 and 40 in the phenol and tertiary amine aglycone substrate selectivities of UDP-glucuronosyltransferases 1A3 and 1A4. Mol Pharmacol 72:1054-1062.
12. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP-glucuronosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 75:677-685.
13. Mazoit JX and Samii K (1999) Binding of propofol to blood components: implications for pharmacokinetics and for pharmacodynamics. Br J Clin Pharmacol 47:35-42.
14. McLure JA, Miners JO, and Birkett DJ (2000) Non-specific binding of drugs to human liver microsomes. Br J Clin Pharmacol 49:453-461.
15. Miners JO and Mackenzie PI (1991) Drug glucuronidation in humans. Pharmacol Ther 51:347-369.
16. Miners JO, Knights KM, Houston JB, and Mackenzie PI (2006) In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531-1539.
17. Miners JO, Smith PA, Sorich MJ, McKinnon RA, and Mackenzie PI (2004) Predicting human drug glucuronidation parameters: applications of in vitro and in silico modelling approaches. Annu Rev Pharmacol Toxicol 44:1-25.
18. Morgan DJ, Campbell GA, and Crankshaw DP (1990) Pharmacokinetics of propofol when given by intravenous infusion. Br J Clin Pharmacol 30:144-148.
19. Ohta Y, Fukushima S, Yamashita N, Niimi T, Kubota T, Akizawa E, and Koiwai O (2005) UDP-glucuronosyltransferase 1A1 directly binds to albumin. Hepatol Res 31:241-245.
20. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, and Miners JO (2006) In vitro characterisation of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 34:1055-1062.
21. Rowland A, Elliot DJ, Knights KM, Mackenzie PI, and Miners JO (2008). The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. Drug Metab Dispos 5:870-877.
22. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, and Miners JO (2007) Binding of inhibitory fatty acids is responsible for the enhancement of UDP glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 321:137-147.
23. Servin F, Desmonts JM, Haberer JP, Cockshott ID, Plummer GF, and Farinotti R (1988) Pharmacokinetics and protein binding of propofol in patients with cirrhosis. Anesthesiology 69:887-891.
24. 14C-propofol. Xenobiotica 18:429-440.
25. Soars MG, Burchell B, and Riley RJ (2002) In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382-390.
26. Sorich MJ, Smith PA, McKinnon RA, and Miners JO (2002) Pharmacophore and quantitative structure activity relationship modelling of UDP- glucuronosyltransferase 1A1 (UGT1A1) substrates. Pharmacogenetics 12:635-645.
27. Tsoutsikos P, Miners JO, Stapleton A, Thomas A, Sallustio BC, and Knights KM (2004) Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem Pharmacol 67:191-199.
28. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression and disease. Annu Rev Pharmacol Toxicol 40:581-616.
29. Uchaipichat V, Elliot DJ, Mackenzie PI, and Miners JO (2006a) Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenein, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes"' for human UDP-glucuronosyltransferases. Drug Metab Dispos 34:449-456.
30. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, and Miners JO (2004) Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413-423.
31. Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, and Miners JO (2006b) Quantitative prediction of in vivo inhibitory drug interactions involving glucuronidated drugs from in vitro data: The effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 61:427-439.
32. Udomuksorn W, Elliot DJ, Lewis BC, Mackenzie PI, Yoovathaworn K, and Miners JO (2007) Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genomics 17:1017-1029.
33. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, and Ball SE (2004) Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208.